Biography

Dr. Rosenberg is a Professor of Neurology with joint appointments in Cell Biology, Neuroscience and Mathematics and Statistics. He joined the faculty of Neurology in 1976, and is currently the Director of the New Mexico Alzheimer’s Disease Research Center (NM ADRC). He is the Founding Director of the UNM Center of Memory and Aging. From 1985 to 2015 he served as Chairman of Neurology, and has trained many neurologists. He graduated from the Albert Einstein College of Medicine and trained there in Neurology. He studied biomedical engineering at the Technion University in Haifa, Israel. His current research is on improving diagnosis in patients with dementia by the use of biomarkers and machine learning. He is an expert in vascular cognitive impairment. He has published over 168 papers and written two books. He has been continuously funded by NIH since 1983, and is now the Principal Investigator on two large NIH grants.

Personal Statement

I am a Clinician-Scientist with clinical training in Neurology under Dr. Robert Katzman. Throughout my career I have been involved in research of the pathobiology of neurological disorders. Early studies in animals were on the role of interstitial fluid (ISF) and cerebrospinal fluid (CSF). I showed that ISF moves primarily in the white matter by bulk flow rather than diffusion. This work was important for understanding the white matter injury that are involved in vascular cognitive impairment and dementia (VCID). I spent a sabbatical with Professor Michael Bradbury at King’s College in London, where I learned methods to study blood-brain barrier (BBB) physiology in rodents. My interest in the ISF and extracellular matrix (ECM), lead to the discovery of the role of matrix-metalloproteinases (MMPs) in disruption of the BBB; this work has been extensively quoted and remains a major focus of interest by many investigators. As part of the studies in the ECM, I discovered that bacterial collagenase induced an intracerebral hemorrhage (ICH), leading to one of the most frequently used models of ICH. My current research is on the role of the MMPs in neuroinflammation in dementia. Those studies in rodents have been expanded into humans, and we have developed methods to measure MMPs in CSF. In addition, we adapted to humans the method to measure BBB permeability with contrast-enhanced MRI. White matter changes on MRI are important in both VCID and in Alzheimer’s disease (AD). My early interest in injury to white matter began with a patient that I reported with Binswanger’s disease (BD); this was the first BD patient diagnosed during life by CT and confirmed at autopsy. We showed that MMPs where present in the CSF of patients with VCID and that they were related to the disruption of the BBB. Recently, as part of the MarkVCID consortium, we showed that inflammatory biomarkers in the CSF, such as the MMPs could be used to separate patients with VCID from AD, and to define mixed dementia patients during life. We have a group of MRI experts, biochemists, and statisticians, and as part of VCID, we have worked closely with Charlie DeCarli’s group to identify the optimal biomarkers to use to more precisely classify dementia patients into subgroups. My role in this RFA-driven proposal will be to provide a cohort of patients that have been extensively studied and followed for multiple years with all of the biomarkers selected by MarkVCID, and to work on new methods of analysis.

Areas of Specialty

vascular cognitive impairment and dementia
blood-brain barrier
matrix metalloproteinases
white matter injury
Alzheimer's disease

Achievements & Awards

8/2020-Present Director, New Mexico Exploratory Alzheimer’s Disease Research Center
1/2016-present Director, University of New Mexico Memory and Aging Center
2000-6 months Visiting Scientist, Dept. of Neurology, (Neuropathology), Oxford University
(Professor Margaret Esiri)
7/1998-present Professor of Cell Biology and Physiology, and Neuroscience
7/1996-present Professor of Mathematics and Statistics (Joint), UNM
7/1990-present Professor of Physiology (Joint), UNM
7/1986-present Professor of Neurology, UNM, School of Medicine
7/1985-12/2015 Chairman, Department of Neurology, UNM, School of Medicine
7/1988-6/1996 Staff Physician, VA Hospital, Albuquerque, NM
6/1984-9/1984 Visiting Scientist in the Dept. of Physiology, King's College, London, UK (Professor Michael Bradbury)
7/1982-6/1996 Associate Professor of Mathematics and Statistics (Joint), UNM
7/1981-6/1990 Associate Professor of Physiology (Joint) UNM
7/1981-6/1986 Associate Professor of Neurology, UNM
7/1976-6/1981 Assistant Professor of Neurology, UNM
7/1976-6/1988 Assistant Chief, Neurology Service, VA Hospital, Albuquerque, NM
7/1973-6/1976 Neurology Resident, Albert Einstein College of Medicine
7/1971-6/1973 Graduate Program, Biomedical Engineering, Technion, Haifa, Israel
7/1971-6/1972 Neurology Resident, Technion-Haifa Med School, Haifa, Israel
7/1969-6/1971 General Medical Officer, Sandia Army Base, Albuquerque, NM
7/1968-6/1969 Intern, University of Rochester (Genesee Hospital), Rochester, NY

Key Publications

Other
Rosenberg, Gary, 2016 Vascular cognitive impairment: Biomarkers in diagnosis and molecular targets in therapy. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 361, 4-5 Journal Article Sánchez, K, E Rosenberg, Gary, 2022 Shared Inflammatory Pathology of Stroke and COVID-19. International journal of molecular sciences, vol. 23, Issue 9
Journal Article
Caprihan, A, Raja, R, Hillmer, L, J Erhardt, E, B Prestopnik, J, Thompson, J, Adair, John, Knoefel, Janice, Rosenberg, Gary, 2021 A double-dichotomy clustering of dual pathology dementia patients. Cerebral circulation - cognition and behavior, vol. 2, Issue
Journal Article
Jiang, S, Maphis, N, M Binder, J, Chisholm, D, Weston, L, Duran, W, Peterson, C, Zimmerman, A, Mandell, Michael, Jett, S, D Bigio, E, Geula, C, Mellios-resigned Feb 2024, Nikolaos, Weick, Jason, Rosenberg, Gary, 2021 Proteopathic tau primes and activates interleukin-1? via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell reports, vol. 36, Issue 12, 109720
Journal Article
Maillard, P, Lu, H, Arfanakis, K, Gold, B, T Bauer, C, E Zachariou, V, Stables, L, Wang DJJ, , Jann, K, Seshadri, S, Duering, M, Hillmer, L, J Rosenberg, Gary, Snoussi, H, Sepehrband, F, 2022 Instrumental validation of free water, peak-width of skeletonized mean diffusivity, and white matter hyperintensities: MarkVCID neuroimaging kits. Alzheimer's & dementia (Amsterdam, Netherlands), vol. 14, Issue 1, e12261

Gender

Male

Languages

  • Spanish
  • Hebrew
  • German
  • English